29 completed, 9 recruiting, 7 terminated, 6 not yet recruiting. 61 Phase 2, 13 Phase 3, 8 Phase 1.
Follow Isoniazid: new trials by email Literature Review of Isoniazid trials Research Report on Isoniazid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Re-evaluating the Duration in Children of TB Treatment Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 230 | 2027-02-01 | 2026-11-02 |
| A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) Isoniazid, Rifampin, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 900 | 2026-10-30 | 2026-08-19 |
| A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV Rifapentine, Isoniazid, Dolutegravir - Tuberculosis | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 144 | 2026-09-28 | 2026-11-02 |
| Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | TASK Applied Science | 135 | 2026-09-25 | 2026-09-25 |
| AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 200 | 2026-09-01 | 2026-03-12 |
| Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB Bedaquiline, Isoniazid, rifapentine, Levofloxacin - Tuberculosis, Latent | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 2530 | 2026-05-08 | 2026-10-20 |
| ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 60 mg - Pulmonary Tuberculosis (TB) | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 80 | 2026-01-03 | 2026-01-23 |
| Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis RESP30TB, HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) - Pulmonary Tuberculoses | Phase 2 | Recruiting | Thirty Respiratory Limited | 24 | 2025-10-13 | 2026-01-12 |
| Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-08-20 | 2025-08-19 |
| Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis Rifampin, Isoniazid, Rifapentine (RPT) - Mild Spinal Tuberculosis | Phase 2 | Not yet recruiting | Shandong University | 300 | 2025-04-05 | 2025-04-08 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 341 | 2025-03-11 | 2026-11-02 |
| A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD, Alpibectir 45 mg OD plus Ethionamide 250 mg OD, Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based - Tuberculosis | Phase 2 | Recruiting | TASK Applied Science | 60 | 2025-03-03 | 2025-03-07 |
| Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Rifapentine, Isoniazid - HIV Seropositivity, Pregnancy | Phase 1 / Phase 2 | Active not recruiting | The Aurum Institute NPC | 252 | 2024-01-17 | 2025-12-12 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| ATORvastatin in Pulmonary TUBerculosis Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 440 | 2024-01-03 | 2025-09-25 |
| Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD) - Tuberculous Meningitis | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 330 | 2023-12-07 | 2026-11-18 |
| Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA) - Tuberculosis, Pulmonary, HIV | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 94 | 2023-11-24 | 2026-08-05 |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection | Phase 2 / Phase 3 | Active not recruiting | Centers for Disease Control and Prevention | 288 | 2023-11-21 | 2026-09-21 |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis | Phase 2 | Active not recruiting | Global Alliance for TB Drug Development | 309 | 2023-10-31 | 2026-06-24 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis | Phase 2 | Terminated | Gates Medical Research Institute | 93 | 2023-07-26 | 2026-05-20 |
Showing 20 of 61. Sign in to see all of them.
Tuberculosis (36) · Tuberculosis, Pulmonary (27) · HIV Infections (7) · Latent Tuberculosis (5) · Tuberculosis, Multidrug-Resistant (5) · Tuberculosis, Meningeal (2) · Acquired Immunodeficiency Syndrome (1) · Asthma (1) · Central Nervous System Diseases (1) · Diabetes Mellitus, Type 2 (1) · Extensively Drug-Resistant Tuberculosis (1) · Gram-Positive Bacterial Infections (1) · HIV Seropositivity (1) · Lupus Erythematosus, Systemic (1) · Pneumonia, Pneumocystis (1)
National Institute of Allergy and Infectious Diseases (NIAID) (11) · Centers for Disease Control and Prevention (5) · Johns Hopkins University (4) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (3) · Global Alliance for TB Drug Development (3) · Michael Hoelscher (3) · Obafemi Awolowo University Teaching Hospital (3) · TASK Applied Science (3) · University College, London (2) · University of Cape Town (2) · Amphastar Pharmaceuticals, Inc. (1) · Brigham and Women's Hospital (1) · Dance Biopharm Inc. (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · GSVM Medical College (1)
South Africa (32) · Uganda (15) · Haiti (10) · Tanzania (9) · Brazil (8) · Malawi (8) · Philippines (8) · United States (8) · Kenya (7) · Thailand (7) · Zimbabwe (7) · India (6) · Peru (6) · Vietnam (6) · Botswana (5)
Bolanle A Omotoso, MD (3) · Kelly Dooley, MD, PhD (2) · Marc Weiner, MD (2) · Nicholas Paton (2) · Olanisun O Adewole, MD (2) · Susan Dorman, MD (2) · Andreas Diacon, MD, PhD (1) · Andreas Diacon, Prof (1) · Andreas H Diacon, MD, PhD (1) · Anneke Hesseling, MD (1) · Anthony Garcia-Prats, MD, MSc, PhD (1) · Anthony Podany, PharmD (1) · Avy Violari, MD (1) · Charles D. Mitchell, MD (1)
PMID 33542052, PMID 36808186, PMID 38768617, PMID 15844071, PMID 16776446, PMID 17517835, PMID 18070980, PMID 18230259, PMID 18787216, PMID 19406981, PMID 19564361, PMID 19923475, PMID 20607114, PMID 20660695, PMID 21494548, PMID 21732834, PMID 23433590, PMID 24663014, PMID 26872154, PMID 27159505, PMID 27550361, PMID 28100438, PMID 28739794, PMID 29463526, PMID 29528048, PMID 29584861, PMID 30102705, PMID 31732485, PMID 31932382, PMID 31945300, PMID 31969368, PMID 32564076, PMID 33229425, PMID 33508224, PMID 33834177, PMID 34323955, PMID 34403326, PMID 35175905, PMID 35273049, PMID 35291004, PMID 35315690, PMID 35607710, PMID 36455068, PMID 36966799, PMID 38243296, PMID 38564365, PMID 38568956, PMID 39622823, PMID 39651910, PMID 39793592
U01AI068636 (2), 2019 (1), R01HD074944 (1), U01AI068632 (1), U01AI134585 (1), U01AI170426 (1), U01AI192041 (1), UM1AI068636 (1)